We believe earnings growth will accelerate over the next three years, driven by increased...
SMIFS research reports
Huhtamaki India is trading at attractive valuation and can be bought for 56% upside potential: SMIFS
The company is intentionally avoiding low-margin business opportunities even if that means growing slower...
The company through its acquisition of INEOS Thailand opens new markets globally & materially...
The company has taken significant steps to enhance operational efficiencies including improvements in sourcing,...
DIL’s strong brand recall coupled with deeper penetration and consumers shifting towards affordable branded...
Existing hospitals sustained strong performance, delivering a robust 33% YoY revenue growth
The excitement around recent Anti-dumping duty (ADD) in NBR is waning as finance ministry...
We expect EBITDA per wheel to rise to Rs 264 in FY27E and Rs...
The company has multiple triggers & trading at a steep discount to its large...
Robust performance, Strong growth potential ahead, Maintain BUY! Overall performance was above our expectations....
